All articles by Chemistry World – Page 20

  • Business

    Business roundup: April 2012

    2012-03-28T09:28:00Z

    Pharmaceutical A pill to keep you off the pints? Source: © IStockphoto Beer today, gone tomorrow - Selincro tablets might help patients put their alcohol problems behind them Phase III trials of Selincro (nalmefene) tablets show that it outperforms placebo treatment when used to help patients with ...

  • News

    Note book

    2012-03-28T09:19:53Z

    Short items, April 2012

  • News

    Croatia to slim down funding for science journals

    2012-03-07T14:03:00Z

    The Croatian government has said it will fund only the best journals, leaving some facing an uncertain future

  • Podcast

    March 2012

    2012-03-01T00:00:00Z

    Chemistry World podcast - March 2012 0:37- Calculations find a quadruple carbon-carbon bond4:18- Graphene sheets are made irridescent and superhydrophobic7:10- Paul Kelly discusses an accidental discovery that led to a novel fingerprinting method14:20- Cooperative chemistry gives rotaxanes with multiple rings in surprisingly high yield ...

  • Opinion

    Flashback

    2012-02-24T08:38:55Z

    10 years ago

  • Opinion

    Letters: March 2012

    2012-02-24T08:38:00Z

    The article ’Silver soils’ (Chemistry World, February 2012, p36) highlights some interesting recent events relating to the environmental impact of silver residues. While a wealth of evidence exists to show that silver ions are toxic to lower organisms, there is less evidence that nanocrystalline or other forms of silver present ...

  • Opinion

    Comment

    2012-02-23T13:12:04Z

    To secure public confidence in nanotechnology, we must learn from the past, says Donald Bruce

  • Opinion

    Comment

    2012-02-23T11:38:27Z

    Ian Churcher and Alan Nadin call for the development of more robust synthetic tools to improve small molecule survival rates in the perilous journey from lead to drug

  • News

    In the papers

    2012-02-23T11:24:51Z

    Short items

  • News

    Note book

    2012-02-23T11:24:50Z

    Short items, March 2012

  • News

    News in Brief

    2012-02-23T11:24:49Z

    Short items, March 2012

  • Business

    Business roundup: March 2012

    2012-02-23T11:24:00Z

    Pharmaceutical Collaboration for neglected tropical diseases A group of 13 pharma companies, three national governments and several global health organisations has come together to target 10 neglected tropical diseases (NTDs) with $785 million (?497 million) in R&D funding. The group aims to ’accelerate progress toward eliminating or controlling [this set ...

  • News

    EU innovation position slipping

    2012-02-17T08:55:00Z

    The growth of innovation in the EU is slowing, making it more difficult for the EU to compete internationally

  • Podcast

    February 2012

    2012-02-01T00:00:00Z

    Chemistry World podcast - February 20121.07 - Determining the age of bloodstains using fluorescence 3.51 - Magnetic nanoparticles to remove cadmium from blood 6.07 - Paul Bertsch discusses using worms to investigate the effects of silver nanoparticles in the environment12.12 - Controlling termite populations with nanoparticle technology15.04 - Listening to ...

  • Opinion

    Flashback

    2012-01-27T10:57:32Z

    30 years ago

  • Opinion

    Letters: February 2012

    2012-01-27T10:57:00Z

    In his comment article, David Fox (Chemistry World, January 2012, p42) highlights the importance of having access to a well-curated repository of small molecules for drug discovery (and chemical genomics), but he feels that it is important to ’combine a well-validated target with a means of intervention that minimises attrition ...

  • News

    In the papers

    2012-01-27T10:47:21Z

    Short items

  • Opinion

    Comment

    2012-01-27T10:00:21Z

    Manoj Mehrotra discusses the rapid rise of outsourcing strategies in research, development and manufacturing

  • Opinion

    Comment

    2012-01-27T09:55:52Z

    The private sector offers significant benefits to public sector labs hampered by bureaucracy and financial constraints, argues Quentin Maxwell-Jackson

  • Business

    Business roundup: February 2012

    2012-01-27T09:27:00Z

    Pharmaceutical BMS spends $2.5 billion on antiviral firm Pharma giant Bristol-Myers Squibb (BMS) has struck a deal to buy US biotech Inhibitex for $2.5 billion (?1.6 billion). The move will stock BMS’s pipeline with antivirals, most notably INX-189, a nucleotide polymerase inhibitor which is in Phase II trials for treating ...